GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
You may also be interested in...
Generics of Complex Drugs Must Pass Korea FDA's Bioequivalence Test; Another Positive Development for MNCs
SEOUL - Korea's Food and Drug Administration will soon require medicines made by Korean generic drug makers to pass the agency's bioequivalence test when producing copies of branded originals with more than two active ingredients, also known as complex drugs
Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said
GSK's Launches, Global Expansion Drive Consumer Sales Ahead Of Market
Brand innovation, continued investment in marketing and global expansion help drive up GlaxoSmithKline's consumer health care sales significantly faster than overall market growth, the firm says